KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Free Cash Flow (2016 - 2026)

Pacira BioSciences has reported Free Cash Flow over the past 17 years, most recently at $24.3 million for Q1 2026.

  • For Q1 2026, Free Cash Flow fell 9.64% year-over-year to $24.3 million; the TTM value through Mar 2026 reached $147.9 million, down 7.19%, while the annual FY2025 figure was $150.5 million, 15.79% down from the prior year.
  • Free Cash Flow for Q1 2026 was $24.3 million at Pacira BioSciences, down from $57.3 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $57.3 million in Q4 2025 and troughed at $9.3 million in Q2 2025.
  • A 5-year average of $35.8 million and a median of $36.5 million in 2022 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: soared 2429.54% in 2022 and later crashed 83.21% in 2025.
  • Year by year, Free Cash Flow stood at $36.5 million in 2022, then fell by 7.26% to $33.9 million in 2023, then crashed by 32.4% to $22.9 million in 2024, then skyrocketed by 150.26% to $57.3 million in 2025, then plummeted by 57.59% to $24.3 million in 2026.
  • Business Quant data shows Free Cash Flow for PCRX at $24.3 million in Q1 2026, $57.3 million in Q4 2025, and $57.0 million in Q3 2025.